Inherited monogenic diseases permeate medicine. At the dawn of the genome era, our understanding of the contribution of inherited genetic differences to disease susceptibility is only increasing. Sickle cell disease, the first monogenic disease for which the amino acid and nucleic acid mutations were identified, cautions that knowing the genetic cause of a disease does not easily lead to therapies. There are several potential approaches to treating genetic diseases at the genome level. A particularly intriguing approach is to cure such diseases by correcting the mutation that causes the disease. For sickle cell disease this would entail converting the mutated thymine back to an adenine in codon 6 of the p-globin gene in hematopoietic stem cells and then retrieving the corrected stem cells to the patient as in an autologous stem cell transplant. In the last several years, two major advances have made the possibility of gene correction by gene targeting more promising. The first is the discovery that a DMA double-strand break in the target gene can stimulate gene targeting. We have found that the stimulation can be up to 50,000 fold. The second is our discovery that model zinc finger nucleases can stimulate gene targeting by creating double-strand breaks in the mammalian genome and our preliminary results demonstrating that zinc finger nucleases can be designed to stimulate gene targeting at endogenous sequences. The next step in the study of double-strand break mediated gene targeting is to study the process in primary cells rather than cell lines. This proposal aims to study the process of gene targeting and the use of zinc finger nucleases in hematopoietic progenitor cells. The goal of these studies is both to understand the biology of gene targeting in these cells and to use that understanding to develop targeting as a therapeutic tool to treat monogenic diseases such as sickle cell disease. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL079295-01A1
Application #
7031839
Study Section
Hematopoiesis Study Section (HP)
Program Officer
Thomas, John
Project Start
2006-02-01
Project End
2010-01-31
Budget Start
2006-02-01
Budget End
2007-01-31
Support Year
1
Fiscal Year
2006
Total Cost
$353,250
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pediatrics
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Heim, Crystal; Minniear, Kayla; Dann, Christina Tenenhaus (2011) Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal. Reprod Toxicol 31:454-63
Ellis, Brian L; Potts, Patrick Ryan; Porteus, Matthew H (2011) Creating higher titer lentivirus with caffeine. Hum Gene Ther 22:93-100
Connelly, Jon P; Barker, Jenny C; Pruett-Miller, Shondra et al. (2010) Gene correction by homologous recombination with zinc finger nucleases in primary cells from a mouse model of a generic recessive genetic disease. Mol Ther 18:1103-10
Zou, Jizhong; Maeder, Morgan L; Mali, Prashant et al. (2009) Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5:97-110
Pruett-Miller, Shondra M; Reading, David W; Porter, Shaina N et al. (2009) Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet 5:e1000376
Pruett-Miller, Shondra M; Connelly, Jon P; Maeder, Morgan L et al. (2008) Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. Mol Ther 16:707-17
Maeder, Morgan L; Thibodeau-Beganny, Stacey; Osiak, Anna et al. (2008) Rapid ""open-source"" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 31:294-301
Porteus, Matthew (2008) Design and testing of zinc finger nucleases for use in mammalian cells. Methods Mol Biol 435:47-61
Dann, Christina Tenenhaus; Alvarado, Alma L; Molyneux, Laura A et al. (2008) Spermatogonial stem cell self-renewal requires OCT4, a factor downregulated during retinoic acid-induced differentiation. Stem Cells 26:2928-37
Porteus, Matthew H; Connelly, Jon P; Pruett, Shondra M (2006) A look to future directions in gene therapy research for monogenic diseases. PLoS Genet 2:e133